Invesco’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

Invesco’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-369	Closed	-$20K	–	3877
2018 Q4	$20K	Sell	369 -469	-56%	-$30K	﹤0.01%	3759
2018 Q3	$57K	Sell	838 -7	-0.8%	-$635	﹤0.01%	3812
2018 Q2	$100K	Buy	845 +282	+50%	+$28.3K	﹤0.01%	3775
2018 Q1	$47K	Buy	+563	New	+$63.8K	﹤0.01%	3692

Other funds holding SRRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco's SRRA Position: Q1 2019 in Review

Invesco sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q1 2019, closing a stake of 369 shares — an estimated $20K sold.

Invesco first reported a position in SRRA in Q1 2018 and held it in 4 quarters. The position peaked at $100K in Q2 2018. 59 funds tracked by Wall St. Rank hold SRRA as of Q1 2019.

Invesco reported no remaining Sierra Oncology, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Invesco sold 369 Sierra Oncology, Inc. Common Stock shares in Q1 2019, an estimated $20K.
Invesco first reported a position in Sierra Oncology, Inc. Common Stock in Q1 2018 and held it in 4 quarters.
Invesco's Sierra Oncology, Inc. Common Stock position peaked at $100K in Q2 2018.
59 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q1 2019.

Based on Invesco's 13F filing for Q1 2019, filed 15 May 2019.